Mesa Laboratories, Inc. (MLAB)
77.15
+0.77
(+1.01%)
USD |
NASDAQ |
Dec 04, 16:00
77.26
+0.10
(+0.14%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 426.05M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -38.50% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.727 |
| Price to Book Value | 2.387 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.16 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.001 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 82.43% |
Profile
| Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Clinical Genomics segment division develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations. The Biopharmaceutical Development segment caters and sells automated systems for protein analysis and peptide synthesis solutions. The Calibration Solutions segment focuses on the quality control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications such as renal care, environmental and process monitoring, gas flow, air quality and torque testing, primarily in medical device manufacturing, pharmaceutical manufacturing, laboratory and hospital environments. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO. |
| URL | http://www.mesalabs.com |
| Investor Relations URL | https://investors.mesalabs.com |
| HQ State/Province | Colorado |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Feb. 03, 2026 |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 28, 2025 |
Ratings
Profile
| Mesa Laboratories, Inc. engages in the design, manufacture, and market of instruments and disposable products utilized in healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators. The Clinical Genomics segment division develops, manufactures and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables and services that enable clinical research labs and contract research organizations. The Biopharmaceutical Development segment caters and sells automated systems for protein analysis and peptide synthesis solutions. The Calibration Solutions segment focuses on the quality control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications such as renal care, environmental and process monitoring, gas flow, air quality and torque testing, primarily in medical device manufacturing, pharmaceutical manufacturing, laboratory and hospital environments. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO. |
| URL | http://www.mesalabs.com |
| Investor Relations URL | https://investors.mesalabs.com |
| HQ State/Province | Colorado |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Feb. 03, 2026 |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Nov. 28, 2025 |